CA2866116C - Expansion of alloantigen-reactive regulatory t cells - Google Patents

Expansion of alloantigen-reactive regulatory t cells Download PDF

Info

Publication number
CA2866116C
CA2866116C CA2866116A CA2866116A CA2866116C CA 2866116 C CA2866116 C CA 2866116C CA 2866116 A CA2866116 A CA 2866116A CA 2866116 A CA2866116 A CA 2866116A CA 2866116 C CA2866116 C CA 2866116C
Authority
CA
Canada
Prior art keywords
alloantigen
expansion
cells
reactive
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2866116A
Other languages
English (en)
French (fr)
Other versions
CA2866116A1 (en
Inventor
Qizhi Tang
Jeffrey A. Bluestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2866116A1 publication Critical patent/CA2866116A1/en
Application granted granted Critical
Publication of CA2866116C publication Critical patent/CA2866116C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2866116A 2012-03-02 2013-03-01 Expansion of alloantigen-reactive regulatory t cells Active CA2866116C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606329P 2012-03-02 2012-03-02
US61/606,329 2012-03-02
PCT/US2013/028734 WO2013131045A1 (en) 2012-03-02 2013-03-01 Expansion of alloantigen-reactive regulatory t cells

Publications (2)

Publication Number Publication Date
CA2866116A1 CA2866116A1 (en) 2013-09-06
CA2866116C true CA2866116C (en) 2021-06-15

Family

ID=49083363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2866116A Active CA2866116C (en) 2012-03-02 2013-03-01 Expansion of alloantigen-reactive regulatory t cells

Country Status (8)

Country Link
US (2) US9801911B2 (enExample)
EP (2) EP2820125B1 (enExample)
JP (1) JP6422344B2 (enExample)
CN (1) CN104245923B (enExample)
AU (2) AU2013225721B2 (enExample)
CA (1) CA2866116C (enExample)
ES (1) ES2675317T3 (enExample)
WO (1) WO2013131045A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US20190062706A1 (en) * 2015-10-28 2019-02-28 Life Technologies As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
CN105420190B (zh) * 2016-01-08 2018-07-31 无锡药明生基医药科技有限公司 B27添加剂及其类似物在利用无血清培养基培养淋巴细胞中的应用
EP3216861A1 (en) * 2016-03-11 2017-09-13 Fropharm GmbH Immunoregulatory cells and methods for their production
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
WO2018231803A1 (en) * 2017-06-12 2018-12-20 The Trustees Of Columbia University In The City Of New York Methods for generating polyclonal regulatory t cells
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3892721A4 (en) 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
BR112021021528A2 (pt) * 2019-04-30 2022-04-19 Univ California Expansão ex vivo livre de contas de células t reguladoras humanas
CN110195041B (zh) * 2019-06-20 2023-04-25 威海正生生物科技有限公司 利用ASC三维培养体系获得高活性Tregs细胞的方法
EP3997212A4 (en) 2019-07-09 2024-01-17 The Children's Mercy Hospital GENETICALLY MODIFIED REGULATORY T CELLS
PL238336B1 (pl) * 2019-08-22 2021-08-09 Gdanski Univ Medyczny Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych
WO2022182763A1 (en) * 2021-02-23 2022-09-01 KSQ Therapeutics, Inc. Methods for expanding regulatory t cells
WO2025081193A1 (en) * 2023-10-13 2025-04-17 Northwestern University Antigen specific expansion of regulatory t cells
JP7627920B1 (ja) 2023-12-11 2025-02-07 浩 宮内 移植材料の評価方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
ATE460475T1 (de) 2000-04-11 2010-03-15 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2004090095A2 (en) 2003-04-01 2004-10-21 University Of Southern California Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
CA2552891A1 (en) 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity
CA2655392A1 (en) * 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
KR20100094997A (ko) 2007-11-30 2010-08-27 테라코스, 인크. 생체 외에서 확장된 ｃｄ４＋ｃｄ２５＋ 조절 ｔ 세포를 사용하여 이식편 대 숙주 질환의 영향을 감소시키는 방법
US8658159B2 (en) 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
WO2010129770A1 (en) 2009-05-07 2010-11-11 The University Of Utah Research Foundation Methods for expanding human t regulatory cells and uses of same

Also Published As

Publication number Publication date
CA2866116A1 (en) 2013-09-06
US20180036345A1 (en) 2018-02-08
AU2018219968A1 (en) 2018-09-06
JP6422344B2 (ja) 2018-11-14
EP2820125A4 (en) 2015-07-29
WO2013131045A1 (en) 2013-09-06
EP3366768B1 (en) 2020-07-08
ES2675317T3 (es) 2018-07-10
JP2015513403A (ja) 2015-05-14
EP2820125A1 (en) 2015-01-07
US20150110761A1 (en) 2015-04-23
AU2013225721B2 (en) 2018-06-14
AU2018219968B2 (en) 2020-09-17
CN104245923B (zh) 2018-04-20
AU2013225721A1 (en) 2014-10-09
US9801911B2 (en) 2017-10-31
EP2820125B1 (en) 2018-05-09
EP3366768A1 (en) 2018-08-29
CN104245923A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
CA2866116C (en) Expansion of alloantigen-reactive regulatory t cells
WO2012003377A3 (en) Methods of preparing chorion tissue and products derived therefrom
EP3915582A3 (en) Anti-cd277 antibodies and uses thereof
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
WO2011152566A3 (en) Composition for inducing proliferation or accumulation of regulatory t cells
WO2012092420A3 (en) Methods for cryopreserving and encapsulating cells
MX2011011402A (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2015005944A (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
SG178991A1 (en) Anti-gitr antibodies
GB201111609D0 (en) Copolymers and membranes
CA2981708C (en) EX VIVO PROLIFERATION OF EPITHELIAL CELLS
AU331284S (en) Vacuum cleaner module
MY161601A (en) Films and compositions comprising the same
CA2905610C (en) Hyaluronic acid derivatives
PH12013501311A1 (en) Polymer systems
PH12014501369A1 (en) Oral care compositions
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
WO2014113704A3 (en) Enhanced differentiation of mesenchymal stem cells
WO2017216775A3 (en) Identification of factor that promotes human hsc self-renewal
IN2013MN00733A (enExample)
HK1206786A1 (en) Methods for induction of antigen-specific regulatory t cells
TN2013000201A1 (en) Methods and compositions for drying coal
WO2009058451A3 (en) Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180201